{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:03:38Z","timestamp":1747145018834},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ijaaonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.ijantimicag.2014.03.014","type":"journal-article","created":{"date-parts":[[2014,5,23]],"date-time":"2014-05-23T15:18:06Z","timestamp":1400858286000},"page":"173-177","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effect of fosamprenavir\/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers"],"prefix":"10.1016","volume":"44","author":[{"given":"Birgit S.","family":"Jacobs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela P.H.","family":"Colbers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Velthoven-Graafland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bas J.J.W.","family":"Schouwenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2014.03.014_bib0005","first-page":"27","article-title":"Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus","volume":"66","author":"Cournos","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.ijantimicag.2014.03.014_bib0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1365-2850.2002.00511.x","article-title":"A review of the literature on HIV infection and schizophrenia: implications for research, policy and clinical practice","volume":"9","author":"Gray","year":"2002","journal-title":"J Psychiatr Ment Health Nurs"},{"key":"10.1016\/j.ijantimicag.2014.03.014_bib0015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/schbul\/22.3.465","article-title":"Schizophrenia and HIV","volume":"22","author":"Sewell","year":"1996","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.ijantimicag.2014.03.014_bib0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1468-1293.2003.00142.x","article-title":"Antiretroviral therapy-induced psychosis: case report and brief review of the literature","volume":"4","author":"Foster","year":"2003","journal-title":"HIV Med"},{"key":"10.1016\/j.ijantimicag.2014.03.014_bib0025","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00004714-200208000-00006","article-title":"Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers","volume":"22","author":"Penzak","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.ijantimicag.2014.03.014_bib0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.qai.0000219774.20174.64","article-title":"Lopinavir\/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers","volume":"42","author":"Yeh","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2014.03.014_bib0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clpt.2006.04.014","article-title":"Lopinavir\/ritonavir reduces lamotrigine plasma concentrations in healthy subjects","volume":"80","author":"Van der Lee","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2014.03.014_bib0040","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/clpt.2008.106","article-title":"The effect of atazanavir and atazanavir\/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe","volume":"84","author":"Burger","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2014.03.014_bib0045","series-title":"Zyprexa: summary of product characteristics","author":"European Medicines Agency","year":"2012"},{"key":"10.1016\/j.ijantimicag.2014.03.014_bib0050","series-title":"Telzir: summary of product characteristics","author":"European Medicines Agency","year":"2011"},{"key":"10.1016\/j.ijantimicag.2014.03.014_bib0055","series-title":"Norvir: summary of product characteristics","author":"European Medicines Agency","year":"2012"},{"key":"10.1016\/j.ijantimicag.2014.03.014_bib0060","series-title":"Guideline on the investigation of bioequivalence","author":"European Medicines Agency, Committee for Medicinal Products for Human Use (CMHP)","year":"2010"},{"key":"10.1016\/j.ijantimicag.2014.03.014_bib0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2014.03.014_bib0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00003088-200645020-00002","article-title":"Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug","volume":"45","author":"Wire","year":"2006","journal-title":"Clin Pharmacokinet"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791400137X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791400137X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T09:05:20Z","timestamp":1649063120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485791400137X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S092485791400137X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.03.014","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of fosamprenavir\/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}